Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world. It is the third leading cause of cancer-related mortality. In more than 80% of people liver cancer-related death is due to its poor prognosis. The flavonoids obtained from natural sources have potent therapeutic effects on HCC. The flavonoid rich methanolic fraction obtained from ethyl acetate extract of leaf of Cestrum nocturnum (MFLCN) was analyzed by UPLC-QTOFMS/MS for the presence of different flavonoids. The physiochemical and pharmacokinetics properties of the identified flavonoids were performed by absorption, distribution, metabolism, excretion, and toxicity (ADMET). It was selected on the basis of Lipinski rule and hepatotoxicity evaluations. The potential gene dataset of HCC were taken from gene card database and targets compounds were selected from target net prediction. Gene ontology and pathway enrichment analysis of HCC was performed via enricher and David web tools. Cytoscape was used to visualize targets and network pathways. MFLCN contains 33 flavonoids. Among these flavonoids, apigenin was selected as principal active compound on the basis of their pharmacokinetic and ADMET properties. Apigenin has 92 targets out of 627 total targets related to HCC, while there was13 pathways in the target-pathway network. Results revealed that apigenin regulates cell proliferation and survival, primarily through different signaling pathways like estrogen, VEGF, PI3K/AKT1, TNF, FoXO, and Ras signaling pathways. Thus, integrating network pharmacology prediction with m-RNA and human protein atlas validation could be an effective method for understanding the molecular mechanism of apigenin on HCC.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
The data that support the findings of this study are available from public databases.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):1–28.
Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi KQ, Tada T, et al. The chances of hepatic resection curing hepatocellular carcinoma. J Hepatol. 2020;72(4):711–7.
Al-Reza SM, Rahman A, Ahmed Y, Kang SC. Inhibition of plant pathogen in vitro and in vivo with essential oil and organic extracts of Cestrum nocturnum L. Pestic Biochem Physiol. 2010;96(2):86–92.
Mimaki Y, Watanabe K, Ando Y, Sakuma C, Sashida Y, Furuya S, et al. Flavonol glycosides and steroidal saponins from the leaves of Cestrum nocturnum and their cytotoxictiy. J Nat Prod. 2001;64(1):17–22.
Qadir MI, Murad MSA, Ali M, Saleem M, Farooq AA. Hepatoprotective effect of leaves of aqueous ethanol extract of Cestrum nocturum against paracetamol-induced hepatotoxcity. Bangladesh J Pharmacol. 2014;9(2):167–70.
Wu DP, Lin TY, Lv JY, Chen WY, Bai LR, Zhou Y, et al. Cestrum nocturnum flower extracts attenuate proliferation and induce apoptosis in malignant cells through inducing DNA damage and inducing topoisomerase II activity. Evid Based Complementary Altern Med. 2017;2017(2017):1–8.
Buchbauer G, Jirovetz L. Volatiles of the absolute of Cestrum nocturnum L. J Essent Oil Res. 1995;7(1):5–8.
Ahmad VU, Baqai FT, Fatima T, Ahmad R. A spirostanol glycoside from Cestrum nocturnum. Phytochemistry. 1991;30:3057–306.
Sahai M, Singh M, Singh AK, Hara N, Fujimoto Y. Cestemosides A and B, novel glucosides from the leaves of Cestrum nocturmum. J Chem Res. 1994;1:22–3.
Ahmad VU, Baqai FT, Ahmad R. A Diosgenin tetrasaccharide from Cestrum nocturnum. Z Naturforsch. 1995;50:1104–10.
Valencia-Mejía E, Leon-Wilchez YY, Monribot-Villanueva JL, Ramirez-Vazquez M, Bonilla-Landa I, Guerrero-Analco JA. Isolation and identification of pennogenin tetraglycoside from Cestrum nocturnum (Solanaceae) and Its antifungal activity against Fusarium kuroshium, causal agent of Fusarium Dieback. Molecules. 2022;27(6):1860.
Madunic J, Gajski G, Popic J, Garaj-Vrhovac V. Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett. 2018;28(413):11–22.
Aldawsari MF, Ahmed MM, Fatima F, Anwer MK, Katakam P, Khan A. Development and characterization of calcium-alginate beads of apigenin: in vitro antitumor, antibacterial, and antioxidant activities. Mar Drugs. 2021;19(8):1–16.
Papachristou F, Anninou N, Koukoulis G, Paraskakis S, Sertaridou E, Tsalikidis C, Pitiakoudis M, Simopoulos C, Tsaroucha A. Differential effects of cisplatin combined with the flavonoid apigenin on HepG2, Hep3B, and Huh7 liver cancer cell lines. Mutat Res Genet Toxicol Environ Mutagen. 2021;866:503352.
Zheng PW, Chiang LC, Lin CC. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 2005;76(12):1367–79.
Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19(3):342–53.
Ginwala R, Bhavsar R, Chigbu DI, Jain P, Khan ZK. Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants (Basel). 2019;8(2):35.
Hu XY, Liang JY, Guo XJ, Liu L, Guo YB. Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (DeltaPsim)-mediated apoptosis in hepatocellular carcinoma. Clin Exp Pharma. 2015;42(2):146–53.
Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466–2272.
Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;29(5):e47.
Rawat D, Shrivastava S, Ahmad R, Koiri RK. An overview of natural plant products in the treatment of hepatocellular carcinoma. Med Chem. 2018;18(13):1838–59.
Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun. 2001;287(4):914–20.
Sato F, Matsukawa Y, Matsumoto K, Nishino H, Sakai T. Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem Biophys Res Commun. 1994;204(2):578–84.
Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S, Sakai T. Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int J Oncol. 2005;26(1):185–9.
Czeczot H, Tudek B, Kusztelak J, Szymczyk T, Dobrowolska B, Glinkowska G, et al. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res. 1990;240(3):209–16.
MacGregor JT. Mutagenic and carcinogenic effects of flavonoids, in plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships. New York: A.R. Liss; 1986.
Sung B, Chung HY, Kim ND. Role of apigenin in cancer prevention via induction of apoptosis and autophagy. J Cancer Prev. 2016;21(4):216–26.
Kim TW, Lee HG. Apigenin induces autophagy and cell death by targeting EZH2 under hypoxia conditions in gastric cancer cells. Int J Mol Sci. 2021;22(24):13455.
An L, Lin Y, Li L, Kong M, Lou Y, Wu J, Liu Z. Integrating network pharmacology and experimental validation to investigate the effects and mechanism of Astragalus flavonoids against hepatic fibrosis. Front Pharmacol. 2021;11:1–17.
Berasain C, Ujue Latasa M, Urtasun R, Goni S, Elizalde M, Garcia-Irigoyen O, et al. Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers (Basel). 2011;3(2):2444–61.
Komposch K, Sibilia M. EGFR signaling in liver diseases. Int J Mol Sci. 2016;17(1):1–31.
Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M, et al. Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma combination array analysis. Int J Oncol. 2013;43(1):88–94.
Ren H, Fang J, Ding X, Chen Q. Role and inhibition of SRC signaling in the progression of liver cancer. Open Life Sci. 2016;11(1):513–8.
Mroweh M, Roth G, Decaens T, Marche PN, Lerat H, MacekJílkova Z. Targeting Akt in hepatocellular carcinoma and its tumor microenvironment. Int J Mol Sci. 2021;22(4):1794.
Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Cigliano A, Evert K, et al. The mTORC2-Akt1 cascade is crucial for c-Myc to promote hepato carcinogenesis in mice and humans. Hepatology. 2019;70:1600–13.
Zhao JX, Yuan YW, Cai CF, Shen DY, Chen ML, Ye F, et al. Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis. Oncotarget. 2017;8:66987–7000.
Chen J, Liang J, Liu S, Song S, Guo W, Shen F. Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncol Lett. 2018;15(5):6857–64.
Moeini A, Cornell H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1(2):83–93.
Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, et al. The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2011;19:375–84.
Ngo MHT, Jeng HY, Kuo YC, Diony Nanda JD, Brahmadhi A, Ling TY, et al. The Role of IGF/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22:1931.
Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. PNAS. 1993;90(16):7533–7.
Kanda T, Yokosuka O. The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015;2:91–9.
Chen HN, Chen Y, Zhou ZG, Wei Y, Huang C. A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. Autophagy. 2019;15(4):733–4.
Li J, Wang X, Yang J, Zhao S, Liu T, Wang L. Identification of hub genes in hepatocellular carcinoma Related to progression and prognosis by weighted gene co-expression network analysis. Med Sci Monit. 2020;26:e920854.
Joshi SB, Beer MA, Giepmans BNG, Zuhorn IS. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano. 2020;14(4):4444–55.
The author Pradeep Kumar gratefully acknowledged to UGC, New Delhi (F-1-17-1/2014-15/RGNF-2014-15-SC-UTT-58260) for financial support as a JRF and SRF. Author Kavindra Nath Tiwari acknowledges to Institute of Eminence (IoE) Banaras Hindu University, Varanasi, India for financial support for research work (Scheme No.6031).
This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
The author declares that they have no conflict of interest.
Consent to participate
Consent for publication
Research involving human participants and/or animals
This study does not contain any studies with human participants or animals performed by the author.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kumar, P., Singh, A.K., Verma, P. et al. Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of Cestrum nocturnum L. to uncover mechanism of action on hepatocellular carcinoma. Med Oncol 39, 155 (2022). https://doi.org/10.1007/s12032-022-01759-z
- Hepatocellular carcinoma (HCC)
- Hub gene